Property source-of-funds and entity-buyer AML/CTF red flags

Build the customer and ownership picture first

Establish the purchasing entity's legal name, form, jurisdiction, identifiers, activities, address and representative. Verify the representative's authority and identify any person on whose behalf the purchase is made. Trace ownership through intermediate companies, partnerships, trusts and nominees to relevant natural persons, and test control through voting, appointment powers, trust roles, contracts or practical influence.

For a trust, obtain the deed and amendments and identify the trustee, owners or controllers of a corporate trustee, settlor, appointor, protector, relevant beneficiaries or classes and other controllers as required. Reconcile the legal documents with instructions and the proposed title. An organisation chart supplied by the buyer can guide the work but does not independently verify the chain.

Distinguish source of funds from source of wealth

Source of funds asks how the deposit and completion money were obtained: for example, accumulated savings, a regulated loan, business income, asset sale, inheritance, gift or distribution. Source of wealth asks how the relevant person built their broader net worth over time. A bank transfer identifies the immediate account but may not explain the economic origin of the money.

Seek evidence proportionate to the risk and program trigger. Reliable material might include account history, loan documentation, sale contracts, probate records, audited or credible business records, distribution documents or tax information lawfully provided. Follow the chain across third-party contributors and entities until the explanation is coherent. Avoid requesting sensitive documents without a defined purpose, secure channel and retention control.

Look for combined ownership and funding indicators

Consider indicators together. A legitimate multinational group can have layers; a family trust can receive a documented distribution; an entrepreneur can buy above salary using proceeds from a business sale. The question is whether reliable evidence and a credible purpose explain the structure and funds at the assessed risk level.

• The person directing the purchase has no explained role in the entity, or beneficial ownership changes shortly before exchange or settlement.
• Funds arrive from an unrelated person, opaque offshore entity or jurisdiction inconsistent with the stated business and no credible explanation is provided.
• The buyer uses layered companies, trusts or nominees without being able to explain purpose, control, commercial rationale or the source of acquisition money.
• Transaction value is materially inconsistent with known activity or wealth, or records conflict on names, ownership percentages, controllers or funding origin.
• There are rapid resales, unusual overvaluation or undervaluation, links between both sides, unnecessary complexity or pressure to bypass normal checks.

Escalate through enhanced CDD, not assumptions

Where high risk or another trigger applies, use enhanced CDD measures stated in the program. These can include deeper independent ownership evidence, additional identity verification, corroborated source of funds or wealth, senior management approval, transaction-purpose documents and increased monitoring. Set a clear question for each measure so the review resolves the concern rather than accumulating paper.

If evidence conflicts, pause the affected step and ask the customer to explain. Verify material explanations independently where possible. Record what was accepted, rejected or still uncertain and why. If the risk cannot be managed or CDD cannot be completed, follow the program's restriction, refusal or exit process and consider suspicious reporting without alerting the customer.

Make and preserve the suspicious-matter decision

An SMR is based on reasonable grounds for suspicion, not proof and not a mechanical red-flag score. Consider customer behaviour, ownership, funds, transaction features, explanations and information available across the reporting entity. A plausible explanation can reduce concern only when it is consistent and appropriately supported; a polished document should not override contradictory facts.

Record when suspicion was or was not formed, the information considered, the decision-maker and any reporting deadline. If reporting is required, submit within the current timeframe and maintain tipping-off controls. Continue monitoring the deal because a late nominee, refund, funding substitution or destination change can materially alter the assessment.